NorthWest Biotherapeutics Inc (NWBO): You have an opinion, and I’m sure you va...

tryn2 · 2020-10-01T01:43:49.0130000Z

You have an opinion, and I’m sure you value it... but l don’t think many here would trade you ONE SHARE of NWBO stock for it... even at current value...

Play Episode

6min

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Proactive - Interviews for investors

Anson Resources reaches key milestone with Lithium polishing phase at Green River Project

Anson Resources CEO Bruce Richardson joined Steve Darling from Proactive to announce a major advancement in the company’s lithium production pathway. The company has officially commenced the “polishing” phase of its high-purity lithium chloride (LiCl) eluate at the Green River Lithium Project in Utah, marking a pivotal step toward battery-grade lithium carbonate production. This phase is being carried out using Koch Technology Solutions’ (KTS) advanced Direct Lithium Extraction (DLE) pilot plant. The polishing process, a critical initial step in downstream refinement, is designed to remove trace contaminants that may remain after the DLE stage. The resulting ultra-pure LiCl solution will then be processed through evaporation and carbonation to yield battery-grade lithium carbonate. Richardson explained that after DLE, the LiCl solution undergoes further purification using advanced separation technologies including nanofiltration and reverse osmosis. These techniques are essential to achieving the high purity required for lithium-ion battery applications. Initial batches of the polished LiCl are expected to be completed in the coming weeks. Once complete, the solution will proceed through the final stages of processing, culminating in the production of high-purity lithium carbonate. Richardson also noted the enhanced performance of the DLE process with KTS technology, reporting a lithium recovery rate of approximately 98% and an impurity rejection rate of 99%. These figures represent a significant improvement over previous results, supporting the efficient, cost-effective production of battery-grade materials. This milestone marks a significant leap forward in Anson Resources’ mission to become a key domestic supplier of critical battery materials, reinforcing its strategic role in the growing U.S. clean energy supply chain. Richardson shared observations from a recent industry conference in Korea, noting concerns over tariffs and future investment planning. He poin

Proactive - Interviews for investors

CleanTech Lithium appoints CEO with deep Chile experience and connections

CleanTech Lithium PLC (AIM:CTL, OTCQX:CTLHF) CEO Ignacio Mehech talked with Proactive's Stephen Gunnion about his priorities following his appointment as the company’s new chief executive. Mehech spoke about the company’s immediate focus and his own background in Chile’s mining sector. He described CleanTech as being at “a very special moment in time”, with several key developments underway including the CEOL (special lithium operation contract) negotiations with Chile’s Ministry of Mining, the delivery of a pre-feasibility study, and the search for a strategic partner. “We have gone all the way to produce lithium carbonate battery grade,” Mehech said, noting that the company has successfully piloted direct lithium extraction (DLE) technologies with its brine projects. Reflecting on his decade of experience in Chile’s mining industry, Mehech outlined his previous roles at Albemarle, including as country manager for Chile and VP of external affairs for Latin America. He stressed the importance of maintaining strong relationships with indigenous communities and government stakeholders in Chile, adding that CleanTech already has “a good relationship” that it must continue building on. He concluded by reinforcing the company’s short-term goals: “Finalise the negotiations on the CEOL with the Ministry of Mining, deliver the pre-feasibility study, and look for a strategic partner to develop this project.” For more insights, visit Proactive’s YouTube channel for additional videos. Don’t forget to like this video, subscribe, and enable notifications so you never miss an update. #CleanTechLithium #Lithium #LithiumExtraction #IgnacioMehech #Mining #MiningChile #BatteryMetals #LithiumBrine #StrategicPartnership #DLEtechnology #PreFeasibilityStudy #ProactiveInvestors

Followers	43
Posts	4255
Boards Moderated	0
Alias Born	01/04/2017

Volume:	3,724,387
Day Range:	0.2078 - 0.245
Bid:	0.212
Ask:	0.2175
Last Trade Time:	3:59:44 PM EDT
Total Trades:	767

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

NWBO Detailed Quote

Recent NWBO News

More NWBO News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent NWBO News

Go Ad-Free